Discovery of KT-474a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases.

Authors: Zheng, Xiaozhang, Ji, Nan, Campbell, Veronica, Slavin, Anthony, Zhu, Xiao, Chen, Dapeng, Rong, Haojing, Enerson, Brad, Mayo, Michele, Sharma, Kirti, Browne, Chris M., Klaus, Christine R., Li, Haoran, Massa, Ginny, McDonald, Alice A., Shi, Yatao, Sintchak, Mike, Skouras, Stephanie, Walther, Dirk M., Yuan, Karen

Source: Journal of Medicinal Chemistry; 10/24/2024, Vol. 67 Issue 20, p18022-18037, 16p

Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924

Authors: Milhollen, Michael A., Thomas, Michael P., Narayanan, Usha, Traore, Tary, Riceberg, Jessica, Amidon, Benjamin S., Bence, Neil F., Bolen, Joseph B., Brownell, James, Dick, Lawrence R., Loke, Huay-Keng, McDonald, Alice A., Ma, Jingya, Manfredi, Mark G., Sells, Todd B., Sintchak, Mike D., Yang, Xiaofeng, Xu, Qing, Koenig, Erik M., Gavin, James M., Smith, Peter G.

Source: In Cancer Cell 20 March 2012 21(3):388-401

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.